
Opinion|Videos|October 8, 2024
Unmet Needs in the HFmrEF and HFpEF Landscape
Author(s)Javed Butler, MD, MPH, MBA
Key Takeaways
- Novel therapies for HFmrEF and HFpEF aim to improve symptom management and patient outcomes, addressing current treatment limitations.
- Emerging treatments could reduce hospitalization rates and enhance quality of life for patients with HFmrEF and HFpEF.
Javed Butler, MD, MPH, MBA, discusses the DAPA ECHO trial data presented at European Society of Cardiology Congress 2024, examining the effects of dapagliflozin on myocardial performance in patients with nondiabetic heart failure, including the study’s objective, design, methodology, results, and key clinical implications for the use of dapagliflozin in this population.
Advertisement
Video content above is prompted by the following:
- Based on the new data from the 3 abstracts, what unmet needs could the therapies address within the heart failure (HF) with midrange ejection fraction (EF) and HF with preserved EF landscape?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
FDA Expands Upadacitinib Label for Treating Inflammatory Bowel Disease
2
CVS Pharmacy Completes Acquisition of Select Rite Aid Locations
3
ESMO Congress Marks 50 Years by Showcasing the Future of Cancer Care: Vivek Subbiah, MD
4
Medical School Diversity Declines Following Affirmative Action Repeal
5